<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: following risks", fill: "#e34234"},
{source: "3: following risks", target: "3: operations could", fill: "#e34234"},
{source: "3: operations could", target: "3: seriously harmed", fill: "#e34234"},
{source: "3: following risks", target: "4: community", fill: "#002366"},
{source: "4: community", target: "4: new products", fill: "#002366"},
{source: "4: new products", target: "4: the Duett ", fill: "#002366"},
{source: "4: the Duett ", target: "4: United States ", fill: "#002366"},
{source: "4: United States ", target: "4: represents", fill: "#002366"},
{source: "4: represents", target: "4: largest market", fill: "#002366"},
{source: "4: largest market", target: "4: interventional medical devices", fill: "#002366"},
{source: "4: community", target: "20: commenced operations", fill: "#ace1af"},
{source: "20: commenced operations", target: "20: February ", fill: "#ace1af"},
{source: "20: February ", target: "20: incurred net", fill: "#ace1af"},
{source: "20: incurred net", target: "20: development", fill: "#ace1af"},
{source: "20: development", target: "20: commercialization", fill: "#ace1af"},
{source: "20: commercialization", target: "20: new products", fill: "#ace1af"},
{source: "20: commenced operations", target: "26: may face additional intellectual property", fill: "#e6e6fa"},
{source: "26: may face additional intellectual property", target: "26: intellectual property", fill: "#e6e6fa"},
{source: "26: intellectual property", target: "26: future which", fill: "#e6e6fa"},
{source: "26: future which", target: "26: could prevent us from manufacturing", fill: "#e6e6fa"},
{source: "26: could prevent us from manufacturing", target: "26: liabilities", fill: "#e6e6fa"},
{source: "26: liabilities", target: "26: interventional medical", fill: "#e6e6fa"},
{source: "26: interventional medical", target: "26: characterized by", fill: "#e6e6fa"},
{source: "26: characterized by", target: "26: numerous patent filings", fill: "#e6e6fa"},
{source: "26: numerous patent filings", target: "26: litigation", fill: "#e6e6fa"},
{source: "26: may face additional intellectual property", target: "39: supply from key vendors", fill: "#c0362c"},
{source: "39: supply from key vendors", target: "39: single source", fill: "#c0362c"},
{source: "39: single source", target: "39: thrombin could limit", fill: "#c0362c"},
{source: "39: thrombin could limit", target: "39: manufacture", fill: "#c0362c"},
{source: "39: manufacture", target: "39: purchase components used", fill: "#c0362c"},
{source: "39: purchase components used", target: "39: products from various suppliers", fill: "#c0362c"},
{source: "39: supply from key vendors", target: "55: Comparisons ", fill: "#a1caf1"},
{source: "55: Comparisons ", target: "55: indication", fill: "#a1caf1"},
{source: "55: indication", target: "55: significantly", fill: "#a1caf1"},
{source: "55: significantly", target: "55: in the United States ", fill: "#a1caf1"},
{source: "55: in the United States ", target: "55: United States ", fill: "#a1caf1"},
{source: "55: United States ", target: "55: introduce new products", fill: "#a1caf1"},
{source: "55: introduce new products", target: "55: enhancements", fill: "#a1caf1"},
{source: "55: enhancements", target: "55: acceptance", fill: "#a1caf1"},
{source: "55: acceptance", target: "55: competition", fill: "#a1caf1"},
{source: "55: competition", target: "55: introduction", fill: "#a1caf1"},
{source: "55: introduction", target: "55: alternative", fill: "#a1caf1"},
{source: "55: alternative", target: "55: direct sales force", fill: "#a1caf1"},
{source: "55: direct sales force", target: "55: independent", fill: "#a1caf1"},
{source: "55: independent", target: "55: distributors", fill: "#a1caf1"},
{source: "55: distributors", target: "55: internationally", fill: "#a1caf1"},
{source: "55: internationally", target: "55: intellectual property disputes", fill: "#a1caf1"},
{source: "55: intellectual property disputes", target: "55: orders from independent distributors", fill: "#a1caf1"},
{source: "55: orders from independent distributors", target: "55: key personnel particularly", fill: "#a1caf1"},
{source: "55: key personnel particularly", target: "55: marketing regulatory manufacturing", fill: "#a1caf1"},
{source: "55: marketing regulatory manufacturing", target: "55: development", fill: "#a1caf1"},
{source: "55: development", target: "55: unanticipated delays", fill: "#a1caf1"},
{source: "55: unanticipated delays", target: "55: inability", fill: "#a1caf1"},
{source: "55: inability", target: "55: control costs", fill: "#a1caf1"},
{source: "55: control costs", target: "55: general economic conditions as well as", fill: "#a1caf1"},
{source: "55: general economic conditions as well as", target: "55: seasonal fluctuations", fill: "#a1caf1"},
{source: "55: seasonal fluctuations", target: "55: revenue due", fill: "#a1caf1"},
{source: "55: Comparisons ", target: "60: interventional medical devices", fill: "#7c1c05"},
{source: "60: interventional medical devices", target: "60: highly competitive", fill: "#7c1c05"},
{source: "60: highly competitive", target: "60: competitive", fill: "#7c1c05"},
{source: "60: competitive", target: "60: likely become", fill: "#7c1c05"},
{source: "60: likely become", target: "60: competitors may", fill: "#7c1c05"},
{source: "60: competitors may", target: "60: emerging technologies", fill: "#7c1c05"},
{source: "60: emerging technologies", target: "60: requirements", fill: "#7c1c05"},
{source: "60: requirements", target: "60: products obsolete", fill: "#7c1c05"},
{source: "60: products obsolete", target: "60: existing market", fill: "#7c1c05"},
{source: "60: interventional medical devices", target: "74: may encounter", fill: "#fad6a5"},
{source: "74: may encounter", target: "74: unforeseen difficulties", fill: "#fad6a5"},
{source: "74: unforeseen difficulties", target: "74: new products", fill: "#fad6a5"},
{source: "74: new products", target: "74: production yields quality control", fill: "#fad6a5"},
{source: "74: production yields quality control", target: "74: qualified personnel compliance", fill: "#fad6a5"},
{source: "74: qualified personnel compliance", target: "74: regulations", fill: "#fad6a5"},
{source: "74: regulations", target: "74: requirements", fill: "#fad6a5"},
{source: "74: requirements", target: "74: manufacturing", fill: "#fad6a5"},
{source: "74: manufacturing", target: "74: further regulatory approval", fill: "#fad6a5"},
{source: "74: further regulatory approval", target: "74: new manufacturing", fill: "#fad6a5"},
{source: "74: may encounter", target: "START_HERE", fill: "#fad6a5"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nauru">Nauru</a></td>
      <td>Nauru ( nah-OO-roo or  NOW-roo; Nauruan: Naoero), officially the Republic of Nauru (Nauruan: Repubrikin Naoero) and formerly known as Pleasant Island, is an island country and microstate in Oceania, in the Central Pacific. Its nearest neighbour is Banaba Island in Kiribati, 300 km (190 mi) to the east.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tobacco_packaging_warning_messages">Tobacco packaging warning messages</a></td>
      <td>Tobacco package warning messages are warning messages that appear on the packaging of cigarettes and other tobacco products concerning their health effects. They have been implemented in an effort to enhance the public's awareness of the harmful effects of smoking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Timeline_of_Apple_Inc._products">Timeline of Apple Inc. products</a></td>
      <td>This timeline of Apple Inc. products is a list of all stand-alone Apple II, Macintosh, and other computers, as well as computer peripherals, expansion cards, ancillary products, and consumer electronics sold by Apple Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_design">Product design</a></td>
      <td>Product design as a verb is to create a new product to be sold by a business to its customers. A very broad coefficient and effective generation and development of ideas through a process that leads to new products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_innovation">Product innovation</a></td>
      <td>Product innovation is the creation and subsequent introduction of a good or service that is either new, or an improved version of previous goods or services. This is broader than the normally accepted definition of innovation that includes the invention of new products which, in this context, are still considered innovative.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gross_domestic_product">Gross domestic product</a></td>
      <td>Gross domestic product (GDP) is a monetary measure of the market value of all the final goods and services produced in a specific time period by countries. GDP (nominal) per capita does not, however, reflect differences in the cost of living and the inflation rates of the countries; therefore, using a basis of GDP per capita at purchasing power parity (PPP) may be more useful when comparing living standards between nations, while nominal GDP is more useful comparing national economies on the international market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Godrej_Consumer_Products">Godrej Consumer Products</a></td>
      <td>Godrej Consumer Products Limited (GCPL) is an Indian consumer goods company based in Mumbai, India. GCPL's products include soap, hair colourants, toiletries and liquid detergents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phase-gate_process">Phase-gate process</a></td>
      <td>A phase-gate process (also referred to as a stage-gate process or waterfall process) is a project management technique in which an initiative or project (e.g., new product development, software development, process improvement, business change) is divided into distinct stages or phases, separated by decision points (known as gates).\nAt each gate, continuation is decided by (typically) a manager, steering committee, or governance board.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Burger_King_products">Burger King products</a></td>
      <td>When the predecessor of international fast food restaurant chain Burger King (BK) first opened in 1953, its menu predominantly consisted of hamburgers, French fries, soft drinks, milkshakes, and desserts. After being acquired by its Miami, Florida franchisees and renamed in 1954, BK began expanding its menu by adding the Whopper sandwich in 1957, and has since added non-beef items such as chicken, fish, and vegetarian offerings, including salads and meatless sandwiches.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Functional_requirement">Functional requirement</a></td>
      <td>In software engineering and systems engineering, a functional requirement defines a function of a system or its component, where a function is described as a specification of behavior between inputs and outputs.Functional requirements may involve calculations, technical details, data manipulation and processing, and other specific functionality that define what a system is supposed to accomplish. Behavioral requirements describe all the cases where the system uses the functional requirements, these are captured in use cases.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_(European_Union)">Regulation (European Union)</a></td>
      <td>A regulation is a legal act of the European Union that becomes immediately enforceable as law in all member states simultaneously. Regulations can be distinguished from directives which, at least in principle, need to be transposed into national law.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>VASCULAR SOLUTIONS INC   ITEM 1A   RISK FACTORS               The risks and <font color="blue"><font color="blue">uncertainties</font> described</font> below are not the only ones     facing our company</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font>     to us or that we currently deem <font color="blue">immaterial may also impair</font> our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks</font> occur, our business, financial     condition or results of <font color="blue">operations</font> could be <font color="blue"><font color="blue">seriously harm</font>ed</font></td>
    </tr>
    <tr>
      <td>We will not be successful if the <font color="blue">interventional medical</font> device <font color="blue">community</font>     does not adopt our <font color="blue">new products</font>               During the third quarter of 2000 we commenced sales of our first     product, <font color="blue">the Duett </font>sealing device, <font color="blue">in the <font color="blue">United States</font></font>, which we believe     <font color="blue">represents</font> the <font color="blue">largest market</font> for <font color="blue">interventional <font color="blue">medical devices</font></font></td>
    </tr>
    <tr>
      <td>We have     not <font color="blue"><font color="blue">become profitable</font> with</font> our sales of the Duett</td>
    </tr>
    <tr>
      <td>In the second half of     2003, we received clearance to commence sales of four new interventional     products  <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend on</font> the medical     <font color="blue">community</font>’s <font color="blue">acceptance</font> of our <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict how quickly</font>,     if  at all, the medical <font color="blue">community</font> will accept our <font color="blue">new products</font>, or, if     accepted, the extent of their use</td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential customers must</font>:         •   believe that our products offer benefits compared to the <font color="blue">methodologies</font>     and/or devices that they are <font color="blue">currently using</font>;         •   use our products and obtain acceptable <font color="blue">clinical outcomes</font>;         •   believe that our products are worth the price that they will be asked     to pay; and         •   be willing to commit the time and resources required to change their     <font color="blue">current methodology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we have only limited experience with sales of our new     products, we have no ability to predict the level of growth in sales of     these products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter <font color="blue">difficult</font>ies</font> in growing our sales of our new     <font color="blue">medical devices</font> <font color="blue">in the <font color="blue">United States</font></font>, our business will be <font color="blue"><font color="blue">seriously harm</font>ed</font></td>
    </tr>
    <tr>
      <td>We have limited working capital to pursue our business               On  <font color="blue">December </font> 31,  2005,  we had dlra4dtta3 million in cash and cash     <font color="blue">equivalents</font>  and  a working capital of dlra10dtta9 million</td>
    </tr>
    <tr>
      <td>During 2005, our     operating <font color="blue">activities</font> resulted in the use of dlra1dtta7 million of cash</td>
    </tr>
    <tr>
      <td>If our sales do not increase, or if we     <font color="blue">encounter unexpected expenses</font>, we will need to <font color="blue">raise <font color="blue">additional</font></font> working     capital</td>
    </tr>
    <tr>
      <td>We have <font color="blue">no commitments</font> for <font color="blue"><font color="blue">additional</font> funding</font> and so our ability to     meet our long-term liquidity needs is uncertain</td>
    </tr>
    <tr>
      <td>If we <font color="blue">raise <font color="blue">additional</font></font>     funds  through the issuance of <font color="blue">equity securities</font>, our <font color="blue"><font color="blue">shareholders</font> may</font>     experience <font color="blue"><font color="blue">significant</font> dilution</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue"><font color="blue">additional</font> financing may</font> not     be available when needed or, if available, financing may not be on terms     favorable to us or our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>If financing is not available when     required  or is not <font color="blue">available on</font> acceptable terms, we may be unable to     develop or market our products or unable to take advantage of business     <font color="blue">opportunities</font>, or we may be required to <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> curtail</font> our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________       We have incurred losses and we may not be profitable in the future               Since we commenced <font color="blue">operations</font> in <font color="blue">February </font>1997, we have <font color="blue">incurred net</font>     losses   primarily   from   costs  relating  to  the  <font color="blue">development</font>  and     <font color="blue">commercialization</font> of our Duett sealing device and <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">At <font color="blue">December </font>    </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra63dtta8 million</td>
    </tr>
    <tr>
      <td>We expect to     continue to <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> invest</font> in our sales and marketing, and research     and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Because of our plans to introduce <font color="blue">new products</font>     and expand our <font color="blue">commercialization</font>, we expect to incur net losses through at     least  the  second quarter of 2006</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">strategies may</font> not be     successful, and we may not <font color="blue">become profitable</font> in any <font color="blue">future period</font> or at all</td>
    </tr>
    <tr>
      <td>If we do <font color="blue">become profitable</font>, we cannot be certain that we can sustain or     <font color="blue">increase profitability on</font> a quarterly or <font color="blue">annual basis</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may face <font color="blue">additional</font> <font color="blue"><font color="blue">intellectual</font> property</font></font> claims in the <font color="blue">future which</font>     <font color="blue">could <font color="blue">prevent us from <font color="blue">manufacturing</font></font></font> and selling our products or result in     our incurring substantial costs and <font color="blue">liabilities</font>               The <font color="blue">interventional medical</font> device industry is <font color="blue">characterized by</font>     <font color="blue">numerous patent filings</font> and frequent and substantial <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the <font color="blue">interventional medical</font> device industry have     employed  <font color="blue">intellectual</font>  property  <font color="blue">litigation</font>  in  an attempt to gain a     <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>We have been subject to two <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">lawsuits concerning</font> our Duett sealing device</td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">settled both</font>     of these <font color="blue"><font color="blue">intellectual</font> property</font> lawsuits, it is possible that <font color="blue">additional</font>     claims relating to <font color="blue">the Duett </font>could be brought in the future</td>
    </tr>
    <tr>
      <td>We also are the     subject of three <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">lawsuits concerning</font> our Vari-Lase     products</td>
    </tr>
    <tr>
      <td>In addition, while we do not believe that any of our <font color="blue">new products</font>     infringes any <font color="blue">existing patent</font>, it is <font color="blue">highly likely</font> that we will become     subject to <font color="blue"><font color="blue">intellectual</font> property</font> claims <font color="blue">with respect</font> to our <font color="blue">new products</font> in     the future</td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font>property <font color="blue">litigation</font> in <font color="blue">recent years</font> has proven to     be very complex, and the outcome of such <font color="blue">litigation</font> is <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse determination</font> in any <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font> or     interference proceedings could prohibit us from selling a product, subject     us  to  <font color="blue">significant</font> <font color="blue">liabilities</font> to <font color="blue">third parties</font> or require us to seek     licenses  from  <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">costs associated with</font> these license     <font color="blue">arrangements</font>  may  be substantial and could include <font color="blue">ongoing royalties</font></td>
    </tr>
    <tr>
      <td>Furthermore,  the  <font color="blue">necessary</font>  licenses  may  not be available to us on     satisfactory terms, if at all</td>
    </tr>
    <tr>
      <td>Adverse <font color="blue">determinations</font> in a judicial or     <font color="blue">administrative proceeding</font> or failure to obtain <font color="blue">necessary</font> licenses could     <font color="blue">prevent us from <font color="blue">manufacturing</font></font> and selling a product</td>
    </tr>
    <tr>
      <td>Our defense of <font color="blue"><font color="blue">intellectual</font> property</font> claims filed in the future,     <font color="blue">regardless</font> of the merits of the complaint, could divert the attention of our     technical and <font color="blue">management personnel away from</font> the <font color="blue">development</font> and marketing     of our products for <font color="blue"><font color="blue">significant</font> periods</font> of time</td>
    </tr>
    <tr>
      <td>The <font color="blue">costs incurred</font> to     future  claims could be substantial and <font color="blue">seriously harm</font> us, even if our     defense is <font color="blue">ultimately successful</font></td>
    </tr>
    <tr>
      <td>The loss of, or interruption of supply from, key vendors, including our     <font color="blue">single source</font> supplier of thrombin, could limit our ability to <font color="blue">manufacture</font>     our products               We <font color="blue">purchase components used</font> in our <font color="blue">products from various suppliers</font>     and rely on a <font color="blue">single source</font> for the thrombin component of our Duett sealing     device and D-Stat products</td>
    </tr>
    <tr>
      <td>There are <font color="blue">currently no</font> FDA-approved <font color="blue">alternative</font>     suppliers of thrombin</td>
    </tr>
    <tr>
      <td>Our <font color="blue">current supply <font color="blue">agreement</font> with</font> our thrombin vendor     terminated in May 2005</td>
    </tr>
    <tr>
      <td>Because it requires FDA approval, establishing our     <font color="blue">new supplier</font> for thrombin requires a lead-time of <font color="blue">at least two years</font> and     involves <font color="blue">significant</font> <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>The <font color="blue">failure by us</font> to complete our     <font color="blue">thrombin <font color="blue">qualification</font></font> project on time and on budget, or the loss of any     other key vendor, may limit our ability to <font color="blue">manufacture</font> our Duett, D-Stat     Flowable and D-Stat Dry products and <font color="blue">could therefore <font color="blue">seriously harm</font></font> our     business</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________       We have purchased a substantial amount of thrombin inventory, and failure to     <font color="blue">both qualify</font> our new source of thrombin and sell an <font color="blue">increasing amount</font> of our     thrombin-based products could cause a substantial inventory write-off</td>
    </tr>
    <tr>
      <td>The  principal  component in all of our <font color="blue">hemostatic products</font> is     thrombin</td>
    </tr>
    <tr>
      <td>Under a previous supply <font color="blue">agreement</font> with our original thrombin     supplier we issued substantial purchase orders prior to its expiration in     2005</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had approximately dlra1dtta4 million of thrombin     from this <font color="blue">original source</font> in inventory</td>
    </tr>
    <tr>
      <td><font color="blue">Currently </font>we are in the process of     qualifying a new source of thrombin, which has required us to purchase and     hold in inventory approximately dlra1dtta7 million of <font color="blue">additional</font> <font color="blue">thrombin as</font> of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We must complete our <font color="blue">qualification</font> work and receive FDA     clearance before we can utilize this new source of <font color="blue">thrombin as</font> a component     in our <font color="blue">hemostatic products</font></td>
    </tr>
    <tr>
      <td>In  addition, if any of our inventory of <font color="blue">thrombin from</font> the     <font color="blue">original source</font> or the new source is destroyed or <font color="blue">otherwise degraded</font>, we     could be exposed to substantial losses</td>
    </tr>
    <tr>
      <td>Our  future  operating  results  are <font color="blue">difficult</font> to predict and may vary     <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> from quarter</font> to quarter, which may adversely affect the price     of our <font color="blue">common stock</font>               The limited history of our sales and our history of losses make     prediction of future operating results <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>You should not rely on our     <font color="blue">past revenue growth as</font> any <font color="blue">indication</font> of <font color="blue">future growth rates</font> or operating     results</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> will likely fall in the event that     our  operating  results  do  not meet the <font color="blue">expectations</font> of analysts and     investors</td>
    </tr>
    <tr>
      <td><font color="blue">Comparisons </font>of our quarterly operating results are an unreliable     <font color="blue">indication</font>  of  our future performance because they are likely to vary     <font color="blue"><font color="blue">significant</font>ly</font> based on many factors, including:         •   the level of sales of our products in the <font color="blue"><font color="blue">United States</font> </font>market;         •   our ability to introduce <font color="blue">new products</font> and <font color="blue">enhancements</font> in a timely     manner;         •   the demand for and <font color="blue">acceptance</font> of our products;         •   the success of our <font color="blue">competition</font> and the <font color="blue">introduction</font> of <font color="blue">alternative</font>     products;         •   our ability to command favorable pricing for our products;         •   the growth of the market for our devices;         •   the expansion and rate of success of our <font color="blue">direct sales force</font> in the     <font color="blue"><font color="blue">United States</font> </font>and our <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">distributors</font> <font color="blue"><font color="blue">international</font>ly</font>;         •   actions relating to ongoing FDA compliance;         •   the effect of <font color="blue"><font color="blue">intellectual</font> property</font> disputes;         •   the size and timing of orders from <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">distributors</font> or     customers;         •   the attraction and retention of key personnel, particularly in sales     and marketing, regulatory, <font color="blue">manufacturing</font> and research and <font color="blue">development</font>;         •   <font color="blue">unanticipated delays</font> or an <font color="blue">inability</font> to <font color="blue">control costs</font>;         •   <font color="blue">general economic conditions as well as</font> those specific to our customers     and markets; and         •   <font color="blue">seasonal fluctuations</font> in <font color="blue">revenue due</font> to the elective nature of some     procedures</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________       We <font color="blue">may face <font color="blue">product <font color="blue">liability</font></font></font> claims that could result in costly <font color="blue">litigation</font>     and <font color="blue">significant</font> <font color="blue">liabilities</font>               The <font color="blue">manufacture</font> and sale of <font color="blue">medical products entail <font color="blue">significant</font> risk</font>     of <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>The medical device industry in general has been     subject to <font color="blue">significant</font> medical malpractice <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">product <font color="blue">liability</font></font>     claims, with or without merit, could result in costly <font color="blue">litigation</font>, reduced     sales,  cause  us  to  incur  <font color="blue">significant</font>  <font color="blue">liabilities</font>  and divert our     management’s time, attention and resources</td>
    </tr>
    <tr>
      <td>Because of our limited operating     history and lack of experience with these claims, we cannot be sure that our     <font color="blue">product <font color="blue">liability</font></font> insurance coverage is adequate or that it will continue to     be available to us on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>The market for <font color="blue">interventional <font color="blue">medical devices</font></font> is <font color="blue">highly <font color="blue">competitive</font></font> and will     <font color="blue">likely become</font> more <font color="blue">competitive</font>, and our <font color="blue"><font color="blue">competitors</font> may</font> be able to respond     more  quickly  to new or <font color="blue">emerging technologies</font> and changes in customer     <font color="blue">requirements</font> that may render our <font color="blue">products obsolete</font>               The <font color="blue">existing market</font> for <font color="blue">interventional <font color="blue">medical devices</font></font> is intensely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We expect <font color="blue">competition</font> to <font color="blue">increase further as companies</font> develop     <font color="blue">new products</font> and/or modify their <font color="blue">existing products</font> to <font color="blue">compete directly with</font>     ours</td>
    </tr>
    <tr>
      <td>Each of our products <font color="blue">encounters</font> <font color="blue">competition</font> from at least several     medical device companies, including Medtronic Inc, Abbot Laboratories, St</td>
    </tr>
    <tr>
      <td>Each of these companies has:         •   better name <font color="blue">recognition</font>;         •   broader product lines;         •   greater sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font>;         •   <font color="blue"><font color="blue">significant</font>ly</font> greater financial resources;         •   larger research and <font color="blue">development</font> staffs and <font color="blue">facilities</font>; and         •   existing <font color="blue">relationships</font> with some of our potential customers</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">effectively compete with</font> these companies</td>
    </tr>
    <tr>
      <td>In     addition,  broad  <font color="blue">product lines may allow</font> our <font color="blue">competitors</font> to negotiate     exclusive, long-term supply contracts and <font color="blue">offer comprehensive pricing</font> for     their products</td>
    </tr>
    <tr>
      <td>Broader <font color="blue">product lines may also provide</font> our <font color="blue">competitors</font> with     a <font color="blue">significant</font> advantage in <font color="blue">marketing competing products</font> to group purchasing     <font color="blue">organizations</font> and other managed care <font color="blue">organizations</font> that are <font color="blue">increasingly</font>     seeking to <font color="blue">reduce costs through centralized purchasing</font></td>
    </tr>
    <tr>
      <td>Greater financial     resources and product <font color="blue">development</font> <font color="blue">capabilities</font> may allow our <font color="blue">competitors</font> to     respond more quickly to new or <font color="blue">emerging technologies</font> and changes in customer     <font color="blue">requirements</font> that may render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">international</font>  sales  are subject to a number of risks that could     <font color="blue">seriously harm</font> our ability to <font color="blue">successfully commercialize</font> our products in any     <font color="blue"><font color="blue">international</font> market</font>               Our <font color="blue"><font color="blue">international</font> sales</font> are subject to <font color="blue">several risks</font>, including:         •   the ability of our <font color="blue">in<font color="blue">dependent</font></font> <font color="blue">distributors</font> to sell our products;         •   the impact of <font color="blue">recessions</font> in <font color="blue">economies outside</font> the <font color="blue">United States</font>;         •   greater <font color="blue">difficult</font>y in <font color="blue">collecting accounts receivable</font> and longer     <font color="blue">collection periods</font>;         •   unexpected changes in regulatory <font color="blue">requirements</font>, tariffs or other trade     barriers;         •   weaker <font color="blue"><font color="blue">intellectual</font> property</font> rights protection in some countries;         •   <font color="blue">potentially adverse tax consequences</font>; and         •   political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________               The occurrence of any of these events could <font color="blue">seriously harm</font> our     future <font color="blue"><font color="blue">international</font> sales</font> and our ability to <font color="blue">successfully commercialize</font> our     products in any <font color="blue"><font color="blue">international</font> market</font></td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience and may <font color="blue">encounter <font color="blue">difficult</font>ies</font> in     our <font color="blue">manufacturing</font> <font color="blue">operations</font> which could <font color="blue">seriously harm</font> our business               We  have  limited experience in <font color="blue">manufacturing</font> our products</td>
    </tr>
    <tr>
      <td>In     particular, we have limited experience in lyophilization, which is a key     <font color="blue">manufacturing</font> step for our D-Stat Dry <font color="blue">hemostatic bandage</font></td>
    </tr>
    <tr>
      <td>We believe our     <font color="blue">facilities</font> are adequate for our projected production of our products for the     foreseeable future, but future facility <font color="blue">requirements</font> will depend largely on     future  sales  of  our products <font color="blue">in the <font color="blue">United States</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter</font>     unforeseen <font color="blue">difficult</font>ies in expanding our production of our <font color="blue">new products</font>,     including  problems  involving  production yields, quality control and     assurance, component supply and shortages of qualified personnel, compliance     with  FDA  <font color="blue">regulations</font>  and  <font color="blue">requirements</font> regarding good <font color="blue">manufacturing</font>     practices, and the need for <font color="blue">further regulatory approval</font> of new <font color="blue">manufacturing</font>     processes</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font><font color="blue">encountered by us</font> in expanding and maintaining our     <font color="blue">manufacturing</font> <font color="blue">capabilities</font> could <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>Our business and results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">seriously harm</font>ed</font> by changes in     third-party <font color="blue">reimbursement policies</font>               We could be <font color="blue"><font color="blue">seriously harm</font>ed</font> by changes in <font color="blue">reimbursement policies</font> of     <font color="blue">governmental</font> or private healthcare payors, particularly to the extent any     changes <font color="blue">affect reimbursement</font> for <font color="blue">catheterization procedures</font> in which our     products are used</td>
    </tr>
    <tr>
      <td>Failure by physicians, hospitals and other users of our     products to obtain <font color="blue">sufficient reimbursement from healthcare payors</font> for     procedures in which our products are used or adverse changes in <font color="blue">governmental</font>     and private third-party payors’ policies toward reimbursement for such     procedures would <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, healthcare providers, including hospitals and     clinics that purchase <font color="blue">medical devices</font> such as our products, generally rely     on third-party payors, principally federal Medicare, state Medicaid and     private health insurance plans, to reimburse all or part of the cost of     <font color="blue">catheterization procedures</font></td>
    </tr>
    <tr>
      <td>Any changes in this <font color="blue">reimbursement system could</font>     <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">international</font> market</font>s, <font color="blue">acceptance</font> of our products is <font color="blue">dependent</font> in     part upon the <font color="blue">availability</font> of <font color="blue">reimbursement within prevailing healthcare</font>     payment  systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement  </font>and  healthcare  payment  systems in     <font color="blue"><font color="blue">international</font> market</font>s vary <font color="blue"><font color="blue">significant</font>ly</font> by country</td>
    </tr>
    <tr>
      <td>Our failure to receive     <font color="blue">international</font> reimbursement approvals could have a <font color="blue">negative impact on market</font>     <font color="blue">acceptance</font> of our products in the markets in which these approvals are     sought</td>
    </tr>
    <tr>
      <td>Our products and our <font color="blue">manufacturing</font> <font color="blue">activities</font> are subject to extensive     <font color="blue">governmental</font> regulation that <font color="blue">could prevent us from selling</font> our products in     the <font color="blue"><font color="blue">United States</font> </font>or introducing new and improved products               Our  products  and our <font color="blue">manufacturing</font> <font color="blue">activities</font> are subject to     extensive <font color="blue">regulation by</font> a number of <font color="blue">governmental</font> agencies, including the FDA     and comparable <font color="blue">international</font> agencies</td>
    </tr>
    <tr>
      <td>We are required to:         •   obtain the clearance of the FDA and <font color="blue">international</font> agencies before we     can market and sell our products;         •   satisfy these agencies’ content <font color="blue">requirements</font> for all of our labeling,     sales and promotional materials; and         •   undergo rigorous <font color="blue">inspections</font> by these agencies</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________               <font color="blue">Compliance </font>with the <font color="blue">regulations</font> of these <font color="blue">agencies may delay</font> or     <font color="blue">prevent us from introducing</font> any new model of our <font color="blue">existing products</font> or other     new  products</td>
    </tr>
    <tr>
      <td>Furthermore, we may be subject to sanctions, including     temporary  or  <font color="blue">permanent suspension</font> of <font color="blue">operations</font>, product recalls and     <font color="blue">marketing restrictions</font> if we fail to <font color="blue">comply with</font> the laws and <font color="blue">regulations</font>     pertaining to our business</td>
    </tr>
    <tr>
      <td>We  are also required to <font color="blue">demonstrate compliance with</font> the FDA’s     quality system <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>The FDA enforces its quality system <font color="blue">regulations</font>     through  pre-approval  and  periodic  post-approval <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">regulations</font> relate to product testing, vendor <font color="blue">qualification</font>, design control     and  quality  assurance,  as  well  as  the maintenance of records and     <font color="blue">documentation</font></td>
    </tr>
    <tr>
      <td>If we are unable to conform to these <font color="blue">regulations</font>, the FDA may     take  actions  which  could  <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">government regulation may</font> be established that could prevent, delay, modify     or <font color="blue">rescind regulatory clearance</font> or approval of our products</td>
    </tr>
  </tbody>
</table>